Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Uterine Bleeding Heavy Clear all
Completed Not applicable Interventional

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

NCT04425577
View directory record Official record
Conditions
Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions
Transabdominal Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 22 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Vaginal Bromocriptine for Treatment of Adenomyosis

NCT01821001
View directory record Official record
Conditions
Adenomyosis
Interventions
Vaginal Bromocriptine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 23, 2026, 8:59 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 23, 2026, 8:59 AM EDT
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 23, 2026, 8:59 AM EDT
Recruiting No phase listed Observational

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

NCT05916469
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional

Delivering tAN to Reduce HMB: The LUNA Study

NCT07326722
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Sparrow Link, Sparrow Link (Sham)
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

NCT00395993
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT02654054
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2020 · Synced Sep 23, 2026, 8:59 AM EDT
Terminated No phase listed Observational

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

NCT05685199
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 40 Years · Female only
Enrollment
15 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 23, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional

Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms

NCT07084714
View directory record Official record
Conditions
Premenstrual Syndrome, Menstrual Cycle, Menstrual Distress (Dysmenorrhea), Menstrual Bleeding, Heavy
Interventions
Moderate Aerobic Exercise
Behavioral
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 23, 2026, 8:59 AM EDT
Completed No phase listed Observational

Bone Mineral Density in Women With Uterine Fibroids or Endometriosis

NCT03744507
View directory record Official record
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding

NCT01280981
View directory record Official record
Conditions
Menorrhagia
Interventions
Tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Sep 23, 2026, 8:59 AM EDT
Not listed No phase listed Observational

Low VW Activity in Adolescent HMB

NCT02933411
View directory record Official record
Conditions
Von Willebrand Factor Deficiency
Interventions
Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ThermaChoice III Under Local Sedation in the Office Setting

NCT00420264
View directory record Official record
Conditions
Heavy Uterine Bleeding
Interventions
Uterine Ablation
Device
Lead sponsor
Female Pelvic Medicine & Urogynecology Institute of Michigan
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 23, 2026, 8:59 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

NCT01391052
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions
Norethindrone acetate pretreatment, No pretreatment
Drug · Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 23, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional Results available

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

NCT01963403
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions
EE 30mcg/LNG 150mcg, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding

NCT01846507
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Tranexamic Acid
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
10 Years to 19 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 23, 2026, 8:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

HMB- Data Collection Methods

NCT02001324
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Web-based data collection, Paper-based data collection
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

NCT00548860
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Female only
Enrollment
2,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 23, 2026, 8:59 AM EDT
Withdrawn Phase 2 Interventional

Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

NCT02794467
View directory record Official record
Conditions
Adenomyosis
Interventions
Epelsiban, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Washington D.C., District of Columbia • West Palm Beach, Florida • Champaign, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

NCT06634719
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 23, 2026, 8:59 AM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

NCT03400956
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Canyon Country, California • Encinitas, California • Huntington Park, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 23, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 23, 2026, 8:59 AM EDT